Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease‐modifying antirheumatic drugs

Aim To identify the incidence and risk factors for hepatitis B virus (HBV) reactivation in rheumatoid arthritis (RA) patients with resolved HBV receiving biological disease‐modifying antirheumatic drugs (bDMARDs). Method Rheumatoid arthritis patients in whom bDMARD therapy was initiated in our depar...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	International journal of rheumatic diseases 2019-04, Vol.22 (4), p.574-582
Hauptverfasser:	Watanabe, Toshiyuki, Fukae, Jun, Fukaya, Shinji, Sawamukai, Norifumi, Isobe, Masato, Matsuhashi, Megumi, Shimizu, Masato, Akikawa, Kazumasa, Tanimura, Kazuhide, Atsumi, Tatsuya, Koike, Takao
Format:	Artikel
Sprache:	eng
Schlagworte:	antibodies against HBV surface antigen biological disease‐modifying antirheumatic drugs HBV reactivation resolved HBV rheumatoid arthritis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!